Providing GLP-1 drugs to 19.7 million Medicare beneficiaries with obesity would cost $268 billion a year, researchers ...

Insulet Corporation saw a significant drop in stock price in 2023 due to concerns over the impact of GLP-1 weight loss drugs ...

(CTN News) – Novo Nordisk A/S (NYSE:NVO) has reported that it retains about sixty percent of the list price of Ozempic and Wegovy, its medications for diabetes and obesity, in the United States. These ...

Public interest in weight loss drugs like Wegovy and Ozempic is surging, but national data on dispensing patterns in the United States is surprisingly scarce. Now, a national study from Michigan ...

We include products we think are useful for our readers. If you buy through links on this page, we may earn a small commission. Here’s our process. Ozempic (semaglutide) can help people with ...

Revolutionary weight-loss injections such as Wegovy and Ozempic reduce the risk of some of the most common and deadly cancers, a major study suggests. Obese patients taking the drugs, which were ...

Taipei, Taiwan – Ozempic is big business in China. Last year, the Danish pharmaceutical giant Novo Nordisk doubled its sales ...

Medically reviewed by Patricia Mikula, PharmDMedically reviewed by Patricia Mikula, PharmD Ozempic and Wegovy (semaglutide) are medications that can help lower your blood sugar, especially if you ...

The new generation of weight-loss drugs were initially developed to treat diabetes and work by mimicking a hormone that regulates insulin levels and appetite. When celebrities started shedding ...

Ozempic and Wegovy (semaglutide) are medications that can help lower your blood sugar, especially if you live with conditions such as diabetes or hyperglycemia (high blood sugar). These ...

Have a question for Alyssa Northrop or our other editors? Ask here for a chance to be featured in a story. Thank you for submitting your question. Keep reading Forbes Advisor for the chance to see ...

While the UK stock market is rising, the Diageo share price is falling. Here, Edward Sheldon looks at what’s going on with ...